Laura Brege

Laura Brege is a senior advisor to BridgeBio Pharma, a clinical-stage biotechnology company developing novel, genetically targeted therapies. Previously, she was the president and chief executive officer of Nodality, Inc., a private company focused on innovative personalized medicine. Prior to joining Nodality in September 2012, Ms. Brege held several senior-level positions at Onyx Pharmaceuticals, Inc., from June 2006 to December 2011, including executive vice president and chief operating officer. While at Onyx, she led multiple functions, including commercialization, strategic planning, corporate development, and medical, scientific, and governmental affairs. Before joining Onyx, Ms. Brege was a general partner at Red Rock Capital Management Inc., a venture capital firm specializing in early stage financing for technology companies since 1999. Prior to Red Rock, she was the senior vice president and chief financial officer at COR Therapeutics Inc. Earlier in her career, Ms. Brege served as vice president and chief financial officer at Flextronics and vice president and treasurer of The Cooper Companies. In addition to Portola, Ms. Brege currently sits on the boards of directors of the public companies ACADIA Pharmaceuticals, Inc., Aratana Therapeutics, Inc., Dynavax Technologies and Pacira Pharmaceuticals, Inc. Ms. Brege earned her B.A. from Ohio University (Honors Tutorial College) and an M.B.A. from the University of Chicago.